Revolutionary HIV Prevention Drug Set to Launch in the US with Affordable Pricing

A groundbreaking drug, Lenacapavir, is poised to make a significant impact in the fight against HIV, with the potential to "end the pandemic" according to UNAids executive director Dr. Winnie Byanyima. The twice-yearly injection has shown remarkable results in clinical trials, preventing HIV infection in individuals. As regulatory approval is expected on June 19, manufacturer Gilead is facing pressure to keep the cost as low as possible. Estimates suggest the drug could be made for as little as $25 (£18.40) per year, including a 30% profit margin, compared to the estimated $25,000 (£18,400) per year for current preventive medications.

Key Takeaways:

• Lenacapavir, a twice-yearly injection, has shown remarkable results in clinical trials, preventing HIV infection in individuals.
• The manufacturer, Gilead, has agreements with six generic companies to allow the production of low-cost versions of Lenacapavir for 120 low-income countries.
• Global price planning for Lenacapavir is underway, taking into account nearly two decades of research and development, constant learning and iteration, and manufacturing investments.
• UNAids executive director Dr. Winnie Byanyima is urging Gilead to make Lenacapavir available and affordable for all who need it, citing concerns that charging 1,000 times more for a medicine with pandemic-ending potential would be abhorrent.
• Researchers estimate that Lenacapavir could be mass produced for $35 to $46 a year, if there was annual demand for 2m doses, falling to $25 at scaled up production of 5m to 10m doses each year.
• In 2023, there were 1.3m new HIV infections, and the World Health Organization says about 10 million people need to take HIV prevention drugs in order to achieve global goals.

Statistics:

• Estimated annual cost of Lenacapavir for current preventive medications: $25,000 (£18,400)
• Estimated annual cost of Lenacapavir for preventive medications if produced in bulk: $25 (£18.40)
• 1.3m new HIV infections in 2023
• 10 million people worldwide need to take HIV prevention drugs to achieve global goals
• 120 low-income countries to receive low-cost versions of Lenacapavir through Gilead's agreements with generic companies
• Gilead to supply doses for about 2 million people at no profit before generic supplies come to market

Sources:

• Dr Andrew Hill, University of Liverpool
• UNAids executive director Dr. Winnie Byanyima
• World Health Organization
• Gilead statement
• Clinical trial results
• Research analysis from the University of Liverpool and others